Voriconazole pharmacogenetics

In their Article, Johan Maertens and colleagues1 showed the results of a randomised, controlled, phase 3 trial comparing posaconazole versus voriconazole for the primary treatment of invasive aspergillosis. Mortality up until day 42 (the primary endpoint) was 44 (15%) of 288 patients for posaconazole versus 59 (21%) of 287 patients for voriconazole.1 The overall incidence of treatment-related adverse events was 10% higher with voriconazole than with posaconazole.1